Member Info for JimiHendrix

The FDA approval for RNR1 will come after NUCE final recommendation I believe (after the evidence period).

The FDA approval expected sooner is for CYP2C19, submission expected early 2026 and approval just a few months after.

Just asked ChatGPT about this line in the RNS, and it does make me think they may not issue all the shares particularly also when considering the 90 day window… “One of the options for raising additional capital is through the issue of new shares in the capital of the Company.”

…

Short version: they’re keeping their options open (and negotiable).

In the circular they say they’re “actively assessing a broad range of financing options” and note that one option is issuing new shares; they don’t list the others because (a) nothing else is signed, (b) naming specifics can weaken their hand or trigger disclosure obligations, and (c) equity is the fastest executable route with cash only to mid-October. 

What are the likely “other options”? In theory: a small convertible/loan or venture debt, a strategic investment/licensing deal, asset sales, grants/R&D credits, or customer/distributor prepayments. But most of these are slower, need collateral or cashflow, or come with strings (e.g., convertibles can be highly dilutive). With weeks of runway, equity (possibly with warrants/retail leg) is the only thing you can usually close fast. 

So, no—omitting a menu of alternatives isn’t them hiding a “nice, non-dilutive” option; it’s standard wording until/unless another route is firm enough to announce. If they do secure a debt/partner deal, they must RNS it

ChatGPT thinks it’s positive for Genedrive…

“The Lancet finding strengthens the clinical pull for clopidogrel in CAD, which expands the overall need for CYP2C19 genotype awareness. That’s a tail-wind for Genedrive’s category. The POC slice grows most if cardiology guidelines/commissioners endorse genotype-guided clopidogrel use at initiation (especially ACS/PCI), where same-day results matter.”

The tests would still need to go through regulatory approvals even if another company bought the IP. After years of waiting the company is almost there.

I do understand why someone might no longer wish to support the company, however I feel like that is wait for the share price to recover and then get out.

Anybody voting NO with the goal of causing administration or privatisation will probably not only cause many holders to lose a lot of money but unfortunately probably also cause a baby out there to lose its hearing as no doubt it would cause test production to stop and the Scottish national rollout to be cancelled.

Just a thought, personally I can’t see any logic in voting no. I do agree though that the directors should either buy a substantial amount of shares or take a significant salary cut until EBITDA positive.

Not quite, 400m would represent 39% of the total enlarged number of shares (approx 925m off top of my head).

The dilution represents the number of shares in issue. I posted a better explanation yesterday.

Louise, it’s so obvious you are trying to spread fear to push the price down so you can buy in cheaper. You’re posting a lot of nonsense.

That 950k trade was a buy, there was no chance of getting 0.55 for selling at that time. Seems some are loading up at the price (huge buying yesterday pm at 0.55).

Https://www.theguardian.com/society/2025/sep/01/stroke-centres-in-england-given-ai-tool-that-will-help-50-of-patients-recover

ChatGPTs opinion…

The NHS’s adoption of AI technology signals openness to advanced diagnostic tools in acute stroke pathways. As stroke units modernize workflows and embrace digital decision-support, Genedrive’s rapid genetic test fits seamlessly as the next logical step after diagnosis: optimizing post-diagnosis drug prescribing.

Moreover, if the AI-enabled triage becomes the standard initial step, it increases the volume of patients receiving same-session stroke care — representing a larger addressable market for Genedrive’s point-of-care test.

They don’t have £600k cash burn lol.

Their operating expenditure (OPEX) is up to £500 per month. Their cash burn takes into consideration income, which means their cash burn is more like £350-400k or less per month.

Sorry, I meant this… basically the fraction of the company each shareholder owns would reduce by 39%. However in reality the value of the company will be more after a fundraise as they’re able to to continue business. Right now it’s valued to fail, due to fear and the unknown. Positive news won’t be far away though I’m quite sure.

• Before: Genedrive has 624,895,408 shares in issue.

• If they issue 400,000,000 new shares, the total becomes 1,024,895,408.

• The new shares’ slice of the enlarged pie is 400,000,000 ÷ 1,024,895,408 ≈ 39%.

• So every existing holder’s ownership % shrinks by ~39% (you keep the same number of shares, but each one represents a smaller slice: your % becomes ~61% of what it was). For example, if you owned 1.00% before, after the full 400m issue you’d own ~0.61%.

The 39% represents how many additional shares can be issued, it’s not the placing price discount, which could even be at a premium considering how low the mcap currently is and the positive company making news on the horizon.

Will only cost them about £15k now to close it, they’ve done well with that.

It closed flat actually, Louise. What a load of nonsense you’ve been posting lol.

Also just a reminder that NHS England are dealing with the implementation guide and toolkit for this, not NICE. NICE will publish it when they receive it from NHSE.

If the company still expect EBITDA positive in H1 2026 then they’ll have no problem raising funds. I expect they’ll raise a small amount in late September/ early October and then more later when more info about NHS implementation is released.

Bear in mind the NHS codeveloped their CYP2C19 point of care test. It would be most bizarre if they don’t commission it, particularly as NICE has already revealed that lab testing won’t be available at all this year due to budget limitations. Next on the recommendation list is Genedrive’s POC.

Gino confirmed in the RNS from a couple of weeks ago that they expect the NHS conclusion to be positive for POC. I just hope something is released this month.

Nice find! https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01562-4/abstract

A drawdown facility will still require issuing new shares. In fact that maybe what they decide to do, but they’ll need the resolutions passed in order to do that. I also strongly urge voters to vote for the resolutions. Remember many of us have millions of shares here, so a lot at stake, and are relying on the company making it through to EBITDA positive, and then upwards and onwards from there.

Well 1.5p is just an example, the point being a 90 day allocation window gives them flexibility to raise a small amount now and more later possibly at a much higher price if positive news lands, such as the implementation guide & toolkit.